Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742846 | 1.00 | KDM1A (0.36) | KDM1ANFKB1NFKB2RELAMAOB | |
| SCHEMBL3744124 | 0.90 | KDM1A (0.37) | KDM1ANFKB1NFKB2RELAMAOB | |
| SCHEMBL3745175 | 0.90 | KDM1A (0.37) | KDM1ANFKB1NFKB2RELAMAOB | |
| SCHEMBL3752901 | 0.90 | KDM1A (0.37) | KDM1ANFKB1NFKB2RELAMAOB | |
| SCHEMBL3749958 | 0.83 | KDM1A (0.37) | KDM1ANFKB1NFKB2RELAMAOB | |
| SCHEMBL3749956 | 0.83 | KDM1A (0.37) | KDM1ANFKB1NFKB2RELAMAOB | |
| SCHEMBL3749962 | 0.83 | KDM1A (0.37) | KDM1ANFKB1NFKB2RELAMAOB | |
| SCHEMBL3750755 | 0.82 | KDM1A (0.36) | KDM1ANFKB1NFKB2RELAMAOB | |
| SCHEMBL3750757 | 0.82 | KDM1A (0.36) | KDM1ANFKB1NFKB2RELAMAOB | |
| SCHEMBL3752660 | 0.82 | KDM1A (0.36) | KDM1ANFKB1NFKB2RELAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834012-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | KDM1A 2597/4885NFKB1 1795/4885NFKB2 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.